Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT06887907Recruiting
Studying megakaryocytes in sickle cell disease
This trial looks at the cells that help make platelets (megakaryocytes) in people with sickle cell disease. By comparing these cells when you are feeling well and during a pain crisis or chest syndrome, researchers hope to learn more about the condition and find better treatments.
Toulouse, FranceAges 18 years+ - NCT03711110Recruiting
Heart-protection plan for older people with certain cancers
This trial looks at strategies to help prevent heart and blood-vessel problems in people over 65 who have certain cancers. It may help by monitoring and treating heart risks early to lower the chance of future cardiovascular events.
Santiago de Compostela, A CoruñaAges 65 years+ - NCT06245746RecruitingPhase 1
Exosomes for low blood counts after chemo in leukemia
This trial tests whether umbilical cord mesenchymal stem cell exosomes can help restore blood cell counts after chemotherapy in adults with acute myeloid leukemia who are in remission. It aims to reduce the risk of infection and bleeding while waiting for bone marrow recovery.
Wuhan, HubeiAges 18–60 - NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Miami Beach, FloridaAges 18 years+ - NCT07277231RecruitingPhase 3
Comparing two drug combinations for untreated CLL
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
Duarte, CaliforniaAges 18 years+ - NCT06022003RecruitingPhase 2
Azacitidine plus gilteritinib for FLT3-mutated AML
This trial tests whether adding an oral chemotherapy pill (azacitidine) to the targeted drug gilteritinib helps people whose FLT3-mutated AML came back or didn't respond after their first treatment. The goal is to see if the combination is more effective than gilteritinib alone.
AmiensAges 18 years+ - NCT06198816Recruiting
Ultrasound and balloon treatment for old leg clots
This study tests a new way to treat long-standing blood clots in the leg using ultrasound waves and a balloon procedure. It aims to improve blood flow and reduce symptoms like swelling and pain for people who haven't gotten better with standard treatments.
Milan, ItalyAges 18–75 - NCT07270835RecruitingPhase 4
Zanubrutinib plus rituximab for HLH with B-cell lymphoma
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
Suzhou, JiangsuAges 14–80 - NCT07271121RecruitingPhase 2
CAR T cells for CD19+ aggressive lymphoma
This trial tests a personalized treatment where your own immune cells are modified to find and kill lymphoma cells that have a protein called CD19. It may be an option if your lymphoma has returned or not responded to standard treatments.
AmmanAges 18–75 - NCT07270770RecruitingPhase 1
A New Drug BY002 for Relapsed Acute Leukemia with Genetic Changes
This phase 1 trial tests a new drug called BY002 for people with certain types of leukemia (AML, ALL, or MPAL) that have come back or not responded to treatment. It focuses on patients whose leukemia has a specific genetic change (KMT2A rearrangement or NPM1 mutation). The goal is to see if BY002 can help control the disease.
Suzhou, JiangsuAges 16 years+ - NCT07276074Recruiting
Antithrombin use review at Strasbourg Hospital
This study looks back at patient records to see how antithrombin (a medicine that helps prevent blood clots) was used in intensive care or during surgery. It does not test a new treatment, but helps doctors understand if the medicine was given appropriately.
StrasbourgAges 18 years+ - NCT07278856RecruitingPhase 1
Ruxolitinib plus CHOP for untreated T-follicular helper cell lymphoma
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT07278882Recruiting
Mobile app support for home maintenance therapy in childhood leukemia
This trial tests whether using a mobile app to track daily medication and weekly blood tests can help children with acute lymphoblastic leukemia (ALL) continue maintenance therapy safely at home, without needing to stay in the hospital.
Tianjin, Tianjin MunicipalityAges Up to 16 years - NCT07270978RecruitingPhase 1
CD33-targeting cells for leukemia with leftover cancer cells
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07275216RecruitingPhase 2
A study of pembrolizumab plus chemo for frail Hodgkin lymphoma patients
This trial tests a combination of the immunotherapy drug pembrolizumab with chemotherapy for people with newly diagnosed Hodgkin lymphoma who are too frail for standard treatment. The goal is to find a safer, effective option for patients who are older or have other health issues.
Duarte, CaliforniaAges 18 years+ - NCT07270861Recruiting
Study of peripheral T-cell lymphoma outcomes in real-world care
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07270679Recruiting
Genetic markers for ovarian damage after chemo
This study is looking for genetic markers that may help predict how chemotherapy affects the ovaries. It's for women who had breast cancer or lymphoma, froze their ovarian tissue before treatment, and finished that treatment at least 6 months ago.
Bologna, BolognaAges 18–38 - NCT07275541Recruiting
Platelet test for early kidney rejection diagnosis
This study tests whether a simple blood test that looks at platelet behavior can help doctors diagnose acute rejection after a kidney transplant. Early detection of rejection may lead to faster treatment and better outcomes.
MartinAges 18 years+ - NCT07272499RecruitingPhase 2
New drug combo for untreated high-risk mantle cell lymphoma
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 14 years+ - NCT07277387Recruiting
Predicting complications in high-risk fever with low white blood cells
This trial studies whether proteins in your blood can predict complications when you have a fever and very low white blood cells after cancer treatment. It aims to help doctors choose the best antibiotics early on.
Barcelona, BarcelonaAges 18 years+ - NCT07274254RecruitingPhase 3
Lidocaine for sickle cell pain crisis in intensive care
This trial tests whether a numbing medicine (lidocaine) given through a vein can help reduce the amount of strong painkillers (morphine or oxycodone) needed for a sickle cell pain crisis or acute chest syndrome. It aims to ease pain and possibly lower side effects from opioids.
BordeauxAges 18 years+ - NCT07270263Recruiting
Lower-dose blood thinners for people with blood cancers
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Gdansk, Pomeranian VoivodeshipAges 18 years+ - NCT07273721RecruitingPhase 2
Testing BT200 in type 2B von Willebrand disease
This trial tests a new medicine called BT200 (rondaptivon pegol) to see if it can safely help people with type 2B von Willebrand disease who have low platelets and recent bleeding problems.
Vienna, State of ViennaAges 18 years+ - NCT07275190Recruiting
Machine learning to tell apart two rare diseases
This trial uses computer models (machine learning) to help doctors better distinguish between two rare conditions that both cause high levels of a certain white blood cell (eosinophil). The goal is to make diagnosis faster and more accurate, which could lead to more targeted treatment.
PaviaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.